Literature DB >> 16151464

Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab.

I Bruns, F Fox, P Reinecke, G Kobbe, R Kronenwett, G Jung, R Haas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16151464     DOI： 10.1038/sj.leu.2403936

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Evolving Therapy of Peripheral T-cell Lymphoma: 2010 and beyond.

Authors:  Francine Foss
Journal:  Ther Adv Hematol       Date:  2011-06

Review 2.  New molecular insights into peripheral T cell lymphomas.

Authors:  Stefano A Pileri; Pier Paolo Piccaluga
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

3.  Angioimmunoblastic T-cell lymphoma: the effect of initial treatment and microvascular density in 31 patients.

Authors:  Shu Zhao; Liangyu Zhang; Minghui Zhang; Guodong Yao; Xiaosan Zhang; Wenhui Zhao; Wei Ren; Jingxuan Wang; Qingyuan Zhang
Journal:  Med Oncol       Date:  2011-10-30       Impact factor: 3.064

Review 4.  Molecular genetics of peripheral T-cell lymphomas.

Authors:  Pier Paolo Piccaluga; Valentina Tabanelli; Stefano A Pileri
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

5.  BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma.

Authors:  Philippe Ratajczak; Christophe Leboeuf; Li Wang; Josette Brière; Irmine Loisel-Ferreira; Catherine Thiéblemont; Wei-Li Zhao; Anne Janin
Journal:  Mod Pathol       Date:  2012-02-10       Impact factor: 7.842

Review 6.  Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas-Implications for Therapy.

Authors:  Eric Tse; Yok-Lam Kwong
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 3.952

7.  Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.

Authors:  Michael Medinger; Natalie Fischer; Alexandar Tzankov
Journal:  J Oncol       Date:  2010-05-24       Impact factor: 4.375

8.  Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion.

Authors:  Xiaoyuan Huang; Xiangyang Bai; Yang Cao; Jingyi Wu; Mei Huang; Duozhuang Tang; Si Tao; Tao Zhu; Yanling Liu; Yang Yang; Xiaoxi Zhou; Yanxia Zhao; Mingfu Wu; Juncheng Wei; Daowen Wang; Gang Xu; Shixuan Wang; Ding Ma; Jianfeng Zhou
Journal:  J Exp Med       Date:  2010-02-22       Impact factor: 14.307

Review 9.  From empiric to mechanism-based therapy for peripheral T cell lymphoma.

Authors:  Andrew M Intlekofer; Anas Younes
Journal:  Int J Hematol       Date:  2014-02-08       Impact factor: 2.490

10.  Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies.

Authors:  N K El-Mallawany; J K Frazer; P Van Vlierberghe; A A Ferrando; S Perkins; M Lim; Y Chu; M S Cairo
Journal:  Blood Cancer J       Date:  2012-04-13       Impact factor: 11.037
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.